KMED — KraneShares Emerging Markets Healthcare Index ETF
Data updated: 2023-11-29
KMED — KraneShares Emerging Markets Healthcare Index ETF. Money Market · $1.95M AUM · 0.79% expense ratio. Holdings, fees, performance and SEC filings.
KMED Fund Overview
KMED — KraneShares Emerging Markets Healthcare Index ETF is a US ETF managed by Krane Shares Trust, categorised as Money Market. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Krane Shares Trust
- Category: Money Market
- Assets under management: $1.95M
- 1-year return: -0.6%
- Ticker: KMED
- SEC CIK: 0001547576
- SEC series ID: S000061164
- Share class ID: C000198138
KMED Investment Objective and Strategy
KraneShares Emerging Markets Healthcare Index ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Krane Shares Trust.
Investment objective
The KraneShares Emerging Markets Healthcare Index ETF (the Fund) seeks to provide investment results that, before fees and expenses, track the price and yield performance of a specific equity securities index. The Funds current index is the Solactive Emerging Markets Healthcare Index (the Underlying Index).
Principal investment strategy
Under normal circumstances, the Fund will invest at least 80% of its total assets in components of the Underlying Index, depositary receipts, including American depositary receipts (ADRs), representing such components, and securities underlying depositary receipts in the Underlying Index. The Underlying Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of emerging market companies in the healthcare business. Securities eligible for inclusion in the Underlying Index include those issued by companies classified by FactSet Revere Business Industry Classification as being engaged in the health technology or health services industries. The types of companies that may be included in the Underlying Index include those engaged in the pharmaceuticals, biotechnology, medical specialties, managed health care, hospital/nursing management, medical/nursing services and services to the health industry businesses.
Emerging market companies include those incorporated in Brazil, Chile, China, Czech Republic, Colombia, Egypt, Greece, Hungary, India, Indonesia, Malaysia, Mexico, Peru, Philippines, Poland, Qatar, Russia, South Africa, Thailand, Turkey or United Arab Emirates. The Underlying Index may include small-cap, mid-cap and large-cap companies. The Underlying Index applies the following screens so that the securities eligible for inclusion in the Underlying Index, at the time of rebalance: (1) are issued by companies with a minimum market capitalization of $100 million; (2) have a minimum average daily trading volume of $1 million as measured over the last six months; (3) must have traded on 90% of the eligible trading days over the last one-month and six month periods; and (4) trade at a price below $10,000 per share.
If the stock does not have a trading history of six months, the stock must have started trading at least three months before being added to the Underlying Index and must have traded on 90% of the eligible trading days during such time. The Underlying Index includes only securities of issuers that have a free float market capitalization of 10% or more of their total market capitalization. Free-float market capitalization is calculated by multiplying a securitys price by the number of shares available in the market, rather than the total number of shares outstanding. The Fund may invest up to 20% of its assets in instruments that are not included in the Underlying Index, but that Krane believes will help the Fund track the Underlying Index. These investments may include equity securities and depositary receipts of issuers whose securities are not components of the Underlying Index, derivative instruments (including swaps, futures, forwards, structured notes and options), other investment companies (including ETFs) and cash or cash equivalents (including money market funds).
The other investment companies in which the Fund may invest may be advised, sponsored or otherwise serviced by Krane and/or its affiliates. The following China-related securities may be included in the Underlying Index and/or represent investments of the Fund: ? China A-Shares, which are shares of companies incorporated in mainland China and traded on the Chinese exchanges. China A-Shares are primarily purchased and sold in the domestic Chinese market. To the extent the Fund invests in China A-Shares, it expects to do so through the Shanghai-Hong Kong Stock Connect Program or Shenzhen-Hong Kong Stock Connect Program (Stock Connect Programs). A Renminbi Qualified Foreign Institutional Investor (RQFII) or Qualified Foreign Institutional Investor (QFII) license may also be acquired to invest directly in China A-Shares.
? China B Shares, which are shares of companies listed on the Shanghai or Shenzhen Stock Exchange but quoted and traded in foreign currencies (such as Hong Kong Dollars or U.S. Dollars), which were primarily created for trading by foreign investors. ? China H Shares, which are shares of companies incorporated in mainland China and listed on the Hong Kong Stock Exchange (H-Shares), where they are traded in Hong Kong dollars and may be traded by foreign investors. ? China N Shares, which are shares of companies with business operations in mainland China and listed on an American stock exchange, such as NYSE or NASDAQ (N-Shares). ? P-Chips, which are shares of private sector companies with a majority of their business operations in mainland China and controlling private Chinese shareholders, which are incorporated outside of mainland China and traded on the Hong Kong Stock Exchange in Hong Kong dollars.
? Red Chips, which are shares of companies with a majority of their business operations in mainland China and controlled by the central, provincial or municipal governments of the PRC, whose shares are traded on the Hong Kong Stock Exchange in Hong Kong dollars. ? S-Chips, which are shares of companies with business operations in mainland China and listed on the Singapore Exchange. S-Chip shares are issued by companies incorporated anywhere, but many are registered in Singapore, the British Virgin Islands, the Cayman Islands, or Bermuda. Although the Fund reserves the right to replicate (or hold all components of) the Underlying Index, the Fund expects to use representative sampling to track the Underlying Index. Representative sampling is a strategy that involves investing in a representative sample of securities that collectively have an investment profile similar to the Underlying Index.
As of June 30, 2018, the Underlying Index included approximately 84 securities of companies with a market capitalization range of $790 million to $39 billion and an average market capitalization of $11.56 billion. The Underlying Index is rebalanced quarterly. The Fund may engage in securities lending. The Fund is non-diversified. To the extent the Underlying Index is concentrated in a particular industry, the Fund is expected to be concentrated in that industry. The Underlying Index includes securities of issuers engaged in the healthcare sector, but its exposure to the industries within that sector are not fixed and subject to change.
KMED Holdings
Top 10 holdings of KraneShares Emerging Markets Healthcare Index ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| International Holding Company P.J.S.C | 4.69% |
| Shenzhen Mindray Bio-Medical Electronics Co Ltd | 4.58% |
| Sun Pharmaceutical Industries Limited | 4.43% |
| Samsung Biologics Co.,ltd. | 4.35% |
| Celltrion, Inc. | 4.24% |
| Aier Eye Hospital Group Co., Ltd. | 3.36% |
| Bangkok Dusit Medical Services Public Company Limited | 3.08% |
| Wuxi Biologics (cayman) Inc. | 3.07% |
| Ihh Healthcare Berhad | 3.06% |
| Rede D'Or Sao Luiz S.A. | 2.96% |
KMED Portfolio Allocation
Asset-class allocation of KraneShares Emerging Markets Healthcare Index ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 100.3% |
| Cash & Equivalents | 1.0% |
KMED Performance
Total returns for KMED (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| 1 year | -0.6% |
| 3 years (annualised) | -13.6% |
KMED Risk Information
Risk metrics for KMED, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.3%
KMED Costs and Fees
KMED costs about $79 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.79%
- Gross expense ratio: 0.79%
- Portfolio turnover: 36%
- Brokerage commissions: 5.47 bps of average net assets (SEC N-CEN)
KMED Cashflows
Over the 12 months to 2023-09, KraneShares Emerging Markets Healthcare Index ETF had net outflows of $1.22K, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2023-09 | $0 |
| 2023-08 | $0 |
| 2023-07 | −$1.22K |
| 2023-06 | $0 |
| 2023-05 | $0 |
| 2023-04 | $0 |
KMED Debt Constituents
No individual debt constituents are reported in KraneShares Emerging Markets Healthcare Index ETF's latest SEC N-PORT filing.
KMED Prospectus and SEC Filings
Official KraneShares Emerging Markets Healthcare Index ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2023-07-28
- Prospectus (485BPOS) — filed 2022-07-29
- Prospectus (485BPOS) — filed 2021-07-30
- Portfolio holdings (N-PORT) — filed 2023-11-29
- Portfolio holdings (N-PORT) — filed 2023-08-29
- Portfolio holdings (N-PORT) — filed 2023-05-30
- Annual census (N-CEN) — filed 2023-06-14
- Annual census (N-CEN) — filed 2022-06-14
Related Funds
Other Money Market funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.